Arrayit Corporation (ARYC) leads and empowers the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure. - Powerful Science for Life
Corporate - Media & Press - Press Release
Arrayit Corporation Debuts Major New Genomics and Proteomics Products in 2015/2016 Catalog
Arrayit Corporation - February 11, 2015, 0833 AM EST
SUNNYVALE, Calif., Feb. 11, 2015 (GLOBE NEWSWIRE) -- Arrayit Corporation (ARYC), a life sciences and molecular diagnostics leader, announces today that the company is debuting major new products and services for the billion dollar genomics and proteomics markets in the company's new full color, image-rich 2015/2016 catalog. Arrayit High-Seq(TM) genomic labeling kits, HuProt(TM) v2.0 19K human proteome microarrays, InnoScan(R) 910 and 1100 microarray scanners, series 3 glass consumables, and TissueMax(TM) personal tissue microarrayers featured in the new catalog are speeding basic research and clinical medicine to improve healthcare, agriculture and food safety.
Arrayit has enhanced its patented and proprietary microarray platform to accelerate the analysis of the human genome and proteome, which are the blueprints that carry out the inherited and real-time instructions of the human body and impart the function of all living organisms. Deeper genomic and proteomic information is leading to pre-symptomatic diagnostic tests, safer medicines and a personalized healthcare paradigm in which patients receive treatments based on their unique complement of genes and proteins. Arrayit's 2015/2016 catalog showcases the new products and services, which are available worldwide through direct sales and a network of 60 international distributors. Arrayit customers include university and government laboratories, life sciences and biotechnology firms and the world's largest pharmaceutical companies.
"We have made a significant R&D investment to create innovative new genomics and proteomics products for the life sciences market," states Arrayit CEO Rene Schena. "The value-added, cost-effective solutions featured in our new catalog will drive company revenues and earnings beginning in the first quarter of this year."
About Arrayit Corporation
Arrayit utilizes its patented and proprietary microarray platform to lead and empower the genetic, research, pharmaceutical, and diagnostic communities through the discovery, development and manufacture of proprietary life science technologies and consumables for disease prevention, treatment and cure.
- Powerful Science for Life(TM)
Visit www.arrayit.com or more information.
Safe Harbor Statement
We have identified forward-looking statements by using words such as "expect", "believe", and "should". Although we believe our expectations are reasonable, our operations involve a number of risks and uncertainties that are beyond our control, and these statements may turn out not to be true. Risk factors associated with our business, including some of the facts set forth herein, are detailed in the Company's Form 10-K for the fiscal year ended December 31, 2013 and in Form 10-Q for the quarterly period ended September 30, 2014.
Copyright 1993-2019 Arrayit Corporation. All rights reserved.